Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Surrozen Inc (SRZN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/09/2025: SRZN (1-star) is a SELL. SELL since 1 days. Profits (-16.72%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $37
1 Year Target Price $37
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -76.38% | Avg. Invested days 20 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 70.98M USD | Price to earnings Ratio - | 1Y Target Price 37 |
Price to earnings Ratio - | 1Y Target Price 37 | ||
Volume (30-day avg) 2 | Beta 0.57 | 52 Weeks Range 5.90 - 18.17 | Updated Date 07/9/2025 |
52 Weeks Range 5.90 - 18.17 | Updated Date 07/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -24.86 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -971.62% |
Management Effectiveness
Return on Assets (TTM) -21.41% | Return on Equity (TTM) -456.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -22693179 | Price to Sales(TTM) 6.1 |
Enterprise Value -22693179 | Price to Sales(TTM) 6.1 | ||
Enterprise Value to Revenue 2.73 | Enterprise Value to EBITDA 0.71 | Shares Outstanding 8562580 | Shares Floating 5400593 |
Shares Outstanding 8562580 | Shares Floating 5400593 | ||
Percent Insiders 4.09 | Percent Institutions 64.55 |
Upturn AI SWOT
Surrozen Inc
Company Overview
History and Background
Surrozen Inc. was a biotechnology company focused on discovering and developing novel regenerative medicines to treat diseases with significant unmet medical needs. Founded in 2016, it aimed to repair and regenerate damaged tissues and organs. The company ceased operations in January 2024.
Core Business Areas
- Regenerative Medicine Development: Focused on discovering and developing novel regenerative medicines targeting the Wnt pathway.
Leadership and Structure
Surrozen Inc. had a leadership team comprised of experienced biotechnology executives and scientists. Details on the organizational structure are no longer relevant due to the company's closure.
Top Products and Market Share
Key Offerings
- SZN-1326: A clinical-stage antibody designed to activate Wnt signaling for the treatment of severe alcoholic hepatitis (sAH) and other liver diseases. The company ceased operations before any significant revenue generation or market share establishment. Key competitors include companies developing other sAH treatments, such as Gilead Sciences (GILD) and Intercept Pharmaceuticals (ICPT). Intercept was acquired by Alfasigma in December 2023.
- SZN-043: A preclinical asset targeting the Wnt pathway for potential treatment of inflammatory bowel disease (IBD). It did not generate revenue, and no market share data exists. Competitors include companies working on IBD therapies like AbbVie (ABBV) and Takeda (TAK).
Market Dynamics
Industry Overview
The regenerative medicine industry is focused on developing therapies that repair or replace damaged tissues and organs. It is a high-risk, high-reward industry with significant unmet medical needs and potential for growth.
Positioning
Surrozen aimed to position itself as a leader in Wnt pathway-targeted regenerative medicine. However, it was in the early stages of development and did not achieve significant market penetration before its closure.
Total Addressable Market (TAM)
The total addressable market for regenerative medicine is estimated to be billions of dollars, with significant potential for growth in various indications. Surrozen aimed to capture a portion of this TAM through its Wnt-targeted therapies, but the company shutdown before achieving market capture.
Upturn SWOT Analysis
Strengths
- Novel Wnt pathway-targeted approach
- Experienced leadership team (at time of operation)
- Promising preclinical and early clinical data (at time of operation)
Weaknesses
- High cash burn rate
- Dependence on financing
- Early stage of development
- Clinical trial risk
- Company closed operations
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Positive clinical trial results
Threats
- Clinical trial failures
- Competition from established therapies
- Regulatory hurdles
- Difficulty in raising capital
Competitors and Market Share
Key Competitors
- GILD
- ABBV
Competitive Landscape
Surrozen faced intense competition from established pharmaceutical companies with significantly more resources and approved products. Its competitive advantage relied on its novel Wnt pathway approach, but it was unable to overcome financial challenges and bring its therapies to market.
Growth Trajectory and Initiatives
Historical Growth: Surrozen's historical growth was limited as it was focused on research and development. The company ceased operations before achieving significant revenue generation.
Future Projections: Future projections are nonexistent due to company closure.
Recent Initiatives: Recent initiatives are irrelevant due to company closure.
Summary
Surrozen Inc. was a biotechnology company focused on regenerative medicine that ultimately ceased operations due to financial constraints. Its novel Wnt pathway approach showed promise, but the company was unable to secure sufficient funding to advance its pipeline. The closure resulted in significant losses for shareholders. The high cash burn rate and early stage of development proved unsustainable. Surrozen's fate underscores the risks inherent in early-stage biotech investments.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (now historical)
- Press Releases (now historical)
- Industry Reports
- Company Website (now defunct)
Disclaimers:
This analysis is based on publicly available information and historical data. The company has ceased operations, rendering much of the data irrelevant for current investment decisions. This analysis should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Surrozen Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2021-01-11 | CEO, President & Director Mr. Craig C. Parker M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 40 | Website https://www.surrozen.com |
Full time employees 40 | Website https://www.surrozen.com | ||
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.